Keyphrases
Genetic Variation
100%
Single nucleotide Polymorphism
100%
Multiple Myeloma
100%
Treatment Effect
100%
Thalidomide
60%
Osteonecrosis of the Jaw
40%
Venous Thromboembolic Events
40%
Bortezomib
40%
Peripheral Neuropathy
40%
Adverse Effects
40%
Maintenance Treatment
40%
Single nucleotide Polymorphism Analysis
40%
High Dose
40%
Interferon-α (IFN-α)
40%
Therapy-related
20%
MBL2 Gene
20%
Further Analysis
20%
Apoptosis Inflammation
20%
DNA Repair
20%
Biological Pathways
20%
NFKB1
20%
Nuclear factor-κB Pathway
20%
Clinical Trials
20%
Buccal Cells
20%
DNA Repair Genes
20%
Nervous System
20%
Septicemia
20%
Blood Cells
20%
Drug Effects
20%
Apoptosis
20%
Apoptotic Genes
20%
Association Study
20%
Polymorphism
20%
Predictive Marker
20%
DNA Gene
20%
Interleukin-1β
20%
Inflammation
20%
Number of Patients
20%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Myeloma
100%
Thalidomide
100%
Jaw Osteonecrosis
66%
Neuropathy
66%
Inflammation
66%
Interferon
66%
Bortezomib
66%
CYP2C8
33%
Infection
33%
Adverse Event
33%
Immunoglobulin Enhancer Binding Protein
33%
Clinical Trial
33%
Septicemia
33%
Immunology and Microbiology
Single Nucleotide Polymorphism
100%
Multiple Myeloma
100%
Genetic Variation
100%
Thalidomide
42%
Jaw
28%
DNA Repair
28%
Programmed Cell Death
28%
Interferon
28%
Drug Megadose
28%
Neurological System
14%
TRAF3
14%
Immunoglobulin Enhancer Binding Protein
14%
IL1B
14%
Drug Effect
14%
Neuroscience
Genetic Variation
100%
Single-Nucleotide Polymorphism
100%
Thalidomide
42%
Adverse Effect
28%
Interferon
28%
Bortezomib
28%
DNA Repair
28%
Neuropathy
28%
Jaw
28%
Programmed Cell Death
28%
Cytochrome P450 2C8
14%
Tumor Necrosis Factor Receptor Associated Factor 3
14%
NFKB1
14%
Nervous System
14%
IL1B
14%
Immunoglobulin Enhancer Binding Protein
14%
Biochemistry, Genetics and Molecular Biology
Single-Nucleotide Polymorphism
100%
Genetic Variation
100%
Candidate Gene
42%
Programmed Cell Death
28%
Interferon
28%
DNA Repair
28%
Drug Megadose
28%
TRAF3
14%
NFKB2
14%
Genetic Divergence
14%
Drug Effect
14%
IL1B
14%
NFKB1
14%
CYP2C8
14%
Clinical Trial
14%
Immunoglobulin Enhancer Binding Protein
14%